Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases
M Zhang, OB Garbuzenko, KR Reuhl… - …, 2012 - Future Medicine
Aims: To develop an approach for the effective treatment of ovarian tumor, prevention of
metastases and limitation of side effects. Materials & Methods: In order to combine …
metastases and limitation of side effects. Materials & Methods: In order to combine …
Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance
J Zhang, J Zhao, W Zhang, G Liu, D Yin, J Li… - International Journal of …, 2012 - ijgc.bmj.com
Objective The objective of this study was to establish a taxol (TAX)–resistant human ovarian
carcinoma cell line and investigate its drug-resistant mechanism. Methods Using the dose …
carcinoma cell line and investigate its drug-resistant mechanism. Methods Using the dose …
卵巢癌化疗耐药机制研究进展
刘澈， 王晶 - 实用肿瘤杂志, 2011 - cqvip.com
卵巢癌是妇科常见的恶性肿瘤, 死亡率居妇科肿瘤之首. 化疗是目前治疗卵巢癌的重要手段之一.
化疗耐药是影响晚期卵巢癌患者预后的主要原因. 卵巢癌化疗耐药是多基因多因素共同参与的 …
化疗耐药是影响晚期卵巢癌患者预后的主要原因. 卵巢癌化疗耐药是多基因多因素共同参与的 …
P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells
JV Chapman, V Gouazé-Andersson, R Karimi… - Experimental cell …, 2011 - Elsevier
Abstract P-glycoprotein (P-gp) antagonists inhibit ceramide metabolism at the juncture of
glycosylation. The purpose of this study was to test whether targeting P-gp would be a viable …
glycosylation. The purpose of this study was to test whether targeting P-gp would be a viable …
卵巢癌化疗耐药相关基因与预后的研究进展
张雯碧， 鹿欣 - 国外医学: 妇产科学分册, 2007 - cqvip.com
卵巢癌是妇科常见的恶性肿瘤, 死亡率居妇科之首. 化疗是目前治疗卵巢癌的重要手段之一.
化疗耐药是影响晚期卵巢癌患者预后的主要原因. 卵巢癌化疗耐药是多基因多因素共同参与的 …
化疗耐药是影响晚期卵巢癌患者预后的主要原因. 卵巢癌化疗耐药是多基因多因素共同参与的 …
MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells
L Ren, L Xiao, J Hu, Z Li, Z Wang - … of Huazhong University of Science and …, 2007 - Springer
To investigate the relationship between MDR1 and MDR3 gene and drug resistance to
cisplatin of ovarian cancer cells. Two siRNAs (MDR1, MDR3) which specifically targeted …
cisplatin of ovarian cancer cells. Two siRNAs (MDR1, MDR3) which specifically targeted …
Effects of alvocidib and carboplatin on ovarian cancer cells in vitro
KH Baumann, H Kim, J Rinke, T Plaum… - Experimental …, 2013 - irbis-nbuv.gov.ua
Aim-failure of platinum chemotherapy is an unresolved issue in ovarian cancer. Targeted
therapy has been added to the treatment options in solid cancers. Alvocidib is a cyclin …
therapy has been added to the treatment options in solid cancers. Alvocidib is a cyclin …
卵巢癌组织中MDR-1, Wnt-1, FZD-1 基因的表达变化及其与化疗耐药的关系
刘博文， 李红霞 - 山东医药, 2010 - cqvip.com
目的观察化疗及非化疗卵巢癌组织中多药耐药基因-1 (MDR-1) 及Wnt-1, FZD-1
基因的表达变化, 探讨其与卵巢癌化疗耐药的关系. 方法卵巢癌患者60 例, 包括紫杉醇化疗组(Ⅰ …
基因的表达变化, 探讨其与卵巢癌化疗耐药的关系. 方法卵巢癌患者60 例, 包括紫杉醇化疗组(Ⅰ …
卵巢癌化疗耐药机制及逆转耐药的研究概况
李久现， 张勤华 - 医学综述, 2011 - cqvip.com
卵巢癌是常见的妇科恶性肿瘤之一, 严重威胁女性健康. 以铂类为基础的联合化疗是治疗卵巢癌
的重要手段, 化疗耐药是卵巢癌复发和治疗失败的最主要原因之一, 导致5 年生存率仍然较低 …
的重要手段, 化疗耐药是卵巢癌复发和治疗失败的最主要原因之一, 导致5 年生存率仍然较低 …
MDR1 基因在上皮性卵巢癌组织中的表达及临床意义
张素娟， 闫洪超， 薛加强 - 实用诊断与治疗杂志, 2007 - cqvip.com
目的: 探讨多药耐药基因(MDR1) 在上皮性卵巢癌组织中的表达及临床意义. 方法: 采用逆转录-
聚合酶链反应(RT—PCR) 测定了37 例上皮性卵巢癌, 32 例卵巢上皮性良性肿瘤和30 …
聚合酶链反应(RT—PCR) 测定了37 例上皮性卵巢癌, 32 例卵巢上皮性良性肿瘤和30 …